gdc

Skin Cancer

Libtayo Extends Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
Skin Cancer
New results presented at the 2020 ASCO annual meeting show that patients with advanced or metastatic (spreading) cutaneous squamous-cell carcinoma (CSCC) who received the PD-1 inhibitor Libtayo (cemiplimab) lived much longer than patients who did not receive this PD-1 inhibitor.
Libtayo Reduces Pain, Improves Quality of Life  in Patients with Advanced Cutaneous  Squamous-Cell Carcinoma
ImmunotherapySkin Cancer
This article reviews the promising findings presented at the 2020 ASCO meeting showing that treatment with the immunotherapy Libtayo may reduce pain and improve survival without disease progression in patients with advanced cutaneous squamous-cell carcinoma, or skin cancer.
Immunotherapy with Libtayo Prolongs Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
ImmunotherapySkin Cancer
Cutaneous squamous-cell carcinoma (CSCC), or skin cancer, is the second most common cancer in the United States. This article examines the results of a recent study on the first and only immunotherapy approved for patients with advanced or metastatic CSCC.
Libtayo Reduces Pain, Improves Quality of Life in Patients with Advanced Cutaneous Squamous-Cell Carcinoma
ImmunotherapySkin Cancer
This article reviews the promising findings presented at the 2020 ASCO meeting showing that treatment with the immunotherapy Libtayo may reduce pain and improve survival without disease progression in patients with advanced cutaneous squamous-cell carcinoma, or skin cancer.
July is UVC Safety Awareness Month
Skin CancerSlideshows
View this slideshow to learn how to protect yourself from harmful ultraviolet radiation.
The Gift of Life After Skin Cancer: From Surgeon to Being a Patient
Clinical TrialsPatient StoriesSkin Cancer
After a lifetime of treating patients, Dr. David Crouch understood his own illness left little room for optimism as skin cancer returned again and again. As a last resort, he joined a clinical trial of a new immunotherapy that provided him a new lease on life. Today, after 2 years in remission, his mission is to educate people about this cancer and this immunotherapy.
Advances in the Treatment of a Rare Type of Skin Cancer: Merkel-Cell Carcinoma
ImmunotherapySkin Cancer
Immunotherapy brings new hope for patients with Merkel-cell carcinoma, a rare type of skin cancer with few treatment options.
August is Summer Sun Safety Month!
Skin CancerSlideshows
August is Summer Sun Safety Month! Learn some of the damaging effects of ultraviolet (UV) exposure, and tips to help you protect yourself during the summer months.
Skin Cancer: Risk Factors and Prevention Strategies
PreventionSkin Cancer
Skin cancer is the most common type of cancer in the United States. Now that summer is here, understand the risk factors and apply prevention measures to avoid skin cancer.
Page 1 of 2
Results 1 - 10 of 15

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country